Appointment of Joint Corporate Broker

RNS Number : 8385T

Oxford Biomedica PLC

27 July 2022

 

Appointment of Joint Corporate Broker

Oxford, UK - 27 July 2022:  Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces the appointment of J.P.Morgan Securities plc (trading as J.P.Morgan Cazenove) as joint corporate broker to work alongside Peel Hunt, with immediate effect.

-Ends-

Enquiries: 

Oxford Biomedica plc: T: [phone] / E: [e-mail]

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Matthew Neal / Matthew Cole 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

 

END

 

 

MSCGZGZNMVLGZZZ